Genmab reported 1.61B in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Agios Pharmaceuticals AGIO:US $ 102.18M 13.03M
AstraZeneca AZN:LN 12.3B 763M
Bayer BAYN:GR 9.1B 154M
Bluebird Bio BLUE:US $ 137.27M 102.36M
Fresenius Medical Care FME:GR 4.2B 262M
Genmab GEN:DC 1.61B 205M
Hikma Pharmaceutical HIK:LN 1.08B 209M
Immunogen IMGN:US $ 60.93M 1.62M
Lonza Group LONN:SW 2.33B 108M
Novartis NOVN:VX 10.96B 826M
William Demant Holding WDH:DC 7.57B 195M